The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Why are elevated liver enzymes a red flag that doctors say shouldn’t be ignored? Keep reading to find out. 🩺 SIGN UP for ...

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

Citigroup has hired Ed Sankey, global head of equity capital markets at HSBC, after HSBC decided in January to close ECM in Europe and the Americas. Sankey is joining Citi as head of ECM for ...

Vascular tumors of the liver in adult patients include cavernous hemangioma, a common benign tumor; epithelioid hemangioendothelioma, a rare, usually low-grade malignant tumor; and angiosarcoma ...

Until now, the only effective long-term treatment for the rare metabolic disease known as severe Carbamoyl Phosphate Synthetase 1 deficiency, or CPS1, had been a liver transplant. Instead ...

School of Pharmacy, Key laboratory of smart drug delivery (Ministry of Education) & National key laboratory of complex drug formulations for overcoming delivery barriers, Fudan University, Shanghai ...

You can find him at Threads @mickmartin182. With the release of the Netflix documentary "Untold: The Liver King", social media fitness influencer Brian Johnson is under fire for promoting his ...

Brian Johnson, a.k.a. the Liver King, is the subject of a new Netflix documentary, Untold: The Liver King. The businessman and gonzo social media influencer promoted a controversial diet comprised ...

Forbes contributors publish independent expert analyses and insights. Monica is an entertainment reporter covering TV, film, and music.

GSK GSK-0.07%decrease; red down pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs.

ALD affects about 26 million patients globally. Together with MASH, it is the leading cause of liver transplants in the U.S. In November 2024, Boston Pharmaceuticals shared results from a Phase 2 ...